UIP is a dubious disease in the field of autoimmunity and rheumatic immunity, clinical performance is complex and often involves multi-system fatigue. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory examination and pathological activation.
A platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment programs for treatment and management of UIP require individual development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and other multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory treatments and precision medicine, many autoimmune and rheumatic immune diseases that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of UIPs associated with synthetase syndrome. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.